Genomes and Genes
central nervous system agents
Summary: A class of drugs producing both physiological and psychological effects through a variety of mechanisms. They can be divided into "specific" agents, e.g., affecting an identifiable molecular mechanism unique to target cells bearing receptors for that agent, and "nonspecific" agents, those producing effects on different target cells and acting by diverse molecular mechanisms. Those with nonspecific mechanisms are generally further classed according to whether they produce behavioral depression or stimulation. Those with specific mechanisms are classed by locus of action or specific therapeutic use. (From Gilman AG, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p252)
Publications240 found, 100 shown here
- Delivery of therapeutic agents to the central nervous system: the problems and the possibilitiesDavid J Begley
Blood Brain Barrier Research Group, GKT School of Biomedical Science, Guy s Campus, King s College London, Hodgkin Building, London SE1 1UL, UK
Pharmacol Ther 104:29-45. 2004..The various strategies available and under development for enhancing drug delivery to the CNS are reviewed...
- Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseasesWolfgang Loscher
Department of Pharmacology, Toxicology, and Pharmacy, University of Veterinary Medicine Hannover, Bunteweg 17, D 30559 Hannover, Germany
Prog Neurobiol 76:22-76. 2005..Finally, we summarize strategies for modulating or by-passing drug efflux transporters at the BBB as novel therapeutic approaches to drug-resistant brain diseases...
- Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humansMartin Brunner
Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, Institute of Medical and Chemical Laboratory Diagnostics, Vienna, Austria
Clin Pharmacol Ther 78:182-90. 2005....
- Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discoveryMohammad S Alavijeh
Pharmidex, London W1S 1RR, United Kingdom
NeuroRx 2:554-71. 2005..This review focuses on BBB penetration, along with pharmacokinetics and drug metabolism, in the process of the discovery and development of safe and effective medicines for CNS disorders...
- Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations?Margareta Hammarlund-Udenaes
Division of Pharmacokinetics and Drug Therapy, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
Basic Clin Pharmacol Toxicol 106:215-20. 2010..However, there is an urgent need to collect more relevant data for predicting active site concentrations in tissues with active transporters in their plasma membranes...
- Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamateKhaled Radad
Institute for Medical Chemistry, Veterinary Medical University, Veterinaerplatz 1, A 1210 Vienna, Austria
Brain Res 1021:41-53. 2004..Thus our study indicates that ginsenosides Rb1 and Rg1 have a partial neurotrophic and neuroprotective role in dopaminergic cell culture...
- Solid lipid nanoparticles for targeted brain drug deliveryPaolo Blasi
Department of Chemistry and Technology of Drugs, School of Pharmacy, University of Perugia, Via del Liceo 1, 06123 Perugia, Italy
Adv Drug Deliv Rev 59:454-77. 2007..A critical consideration on the potential application of such technology as related to the current status of brain drug development is also given...
- Ginsenoside Rg1 promotes nonamyloidgenic cleavage of APP via estrogen receptor signaling to MAPK/ERK and PI3K/AktChun Shi
Department of Anatomy, Guangzhou Medical University, Guangzhou 510182, China
Biochim Biophys Acta 1820:453-60. 2012..However, it is unknown whether Rg1-induced estrogenic activity intervenes in APP processing, and improves memory performance...
- The role of imaging in proof of concept for CNS drug discovery and developmentDean F Wong
Johns Hopkins University School of Medicine, Johns Hopkins University School of Medicine, 601 North Caroline St, JHOC room 3245, Baltimore, MD 21287 0807, USA
Neuropsychopharmacology 34:187-203. 2009..In summary, this article reviews the vital biomarker approach of neuroimaging in proof of concept studies...
- Central nervous system agents for ischemic stroke: neuroprotection mechanismsRachna S Pandya
Brigham and Women s Hospital, Harvard Medical School, Department of Neurosurgery, Boston, Massachusetts 02115, USA
Cent Nerv Syst Agents Med Chem 11:81-97. 2011..This review focuses on central nervous system agents targeting these biochemical pathways and mediators of ischemic stroke, mainly those that counteract ..
- The blood-brain barrier and neurotherapeuticsWilliam M Pardridge
NeuroRx 2:1-2. 2005
- Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systemsAkira Tsuji
Division of Pharmaceutical Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kakuma machi, Kanazawa 920 1192, Japan
NeuroRx 2:54-62. 2005....
- Ginsenoside Rg1 attenuates amyloid-beta content, regulates PKA/CREB activity, and improves cognitive performance in SAMP8 miceYan Qing Shi
Fujian Institute of Geriatrics, Fuzhou, Fujian, People s Republic of China
J Alzheimers Dis 19:977-89. 2010..These data provide further support for the therapeutic or intervention potency of ginsenoside Rg1 in the early stage of AD...
- Ginsenoside Rg1 attenuates β-amyloid generation via suppressing PPARγ-regulated BACE1 activity in N2a-APP695 cellsLi Min Chen
Department of Neurology, Fujian Institute of Geriatrics, the Affiliated Union Hospital of Fujian Medical University, People s Republic of China
Eur J Pharmacol 675:15-21. 2012..Therefore, ginsenoside Rg1 may serve as a promising agent in modulating Aβ-related pathology in Alzheimer's disease...
- Why is the global CNS pharmaceutical market so under-penetrated?William M Pardridge
Drug Discov Today 7:5-7. 2002
- Measurement of the pharmacokinetics and pharmacodynamics of neuroactive compoundsMohammad S Alavijeh
Pharmidex Pharmaceutical Services Ltd, 72 New Bond Street, London, W1S 1RR, UK
Neurobiol Dis 37:38-47. 2010....
- Ginsenosides Rg1 and Rb1 enhance glutamate release through activation of protein kinase A in rat cerebrocortical nerve terminals (synaptosomes)Yi Chang
School of Medicine, Fu Jen Catholic University, 510, Chung Cheng Rd, Hsin Chuang, Taipei Hsien 24205, Taiwan
Eur J Pharmacol 578:28-36. 2008..This finding might provide important information regarding the action of ginseng in the central nervous system...
- Influence of the surface properties on nanoparticle-mediated transport of drugs to the brainJorg Kreuter
Institut fur Pharmazeutische Technologie, Johann Wolfgang Goethe Universitat, Frankfurt, Marie Curie Strasse 9, D 60439 Frankfurt Main, Germany
J Nanosci Nanotechnol 4:484-8. 2004..quot; The drug, then, may be released either within these cells followed by passive diffusion into the brain or be transported into the brain by transcytosis...
- Ginsenoside Rb1 and Rg1 improve spatial learning and increase hippocampal synaptophysin level in miceI Mook-Jung
Brain Disease Research Center, Ajou University School of Medicine, Suwon, Korea
J Neurosci Res 63:509-15. 2001..Our results suggest that Rb1 and Rg1 enhance spatial learning ability by increasing hippocampal synaptic density without changing plasticity of individual synapses...
- Central nervous system agents in the treatment of erectile dysfunction: how do they work?J Allard
Department of Urology, CHU de Bicetre, 78 rue du General Leclerc, 94270 Le Kremlin Bicêtre cedex, France
Curr Urol Rep 2:488-94. 2001..Our knowledge of the mode of action of CNS drugs comes mainly from experiments on rodents. Consequently, explanations regarding the way they work in humans are only speculative...
- Ginsenoside-Rg1 induces vascular endothelial growth factor expression through the glucocorticoid receptor-related phosphatidylinositol 3-kinase/Akt and beta-catenin/T-cell factor-dependent pathway in human endothelial cellsKar Wah Leung
Department of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China
J Biol Chem 281:36280-8. 2006..In addition, the GR antagonist RU486 was able to inhibit Rg1-induced PI3K/Akt and beta-catenin activation. These findings provide new insights into the mechanism responsible for Rg1 functions...
- Getting into the brain: approaches to enhance brain drug deliveryMayur M Patel
Institute of Pharmacy, Nirma University of Science and Technology, Ahmedabad, India
CNS Drugs 23:35-58. 2009..The current challenge is to develop drug delivery strategies that will allow the passage of drug molecules through the BBB in a safe and effective manner...
- Nanoparticle technology for drug delivery across the blood-brain barrierP R Lockman
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo 79106 1712, USA
Drug Dev Ind Pharm 28:1-13. 2002..NP technology appears to have significant promise in delivering therapeutic molecules across the BBB...
- Drug development for CNS disorders: strategies for balancing risk and reducing attritionMenelas N Pangalos
Wyeth Research, Neuroscience Discovery, CN800, Princeton, New Jersey 08543, USA
Nat Rev Drug Discov 6:521-32. 2007....
- Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agentsKatalin Prokai-Tatrai
Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA
Molecules 14:633-54. 2009..The value of prodrug-amenable analogues as potential drug-like central nervous systems agents was highlighted...
- Translational research in central nervous system drug discoveryOrest Hurko
Translational Research, Wyeth, Collegeville, Pennsylvania 19426, USA
NeuroRx 2:671-82. 2005..Implementation of new technologies is the key to success in this emerging endeavor...
- [Physiological function of blood-brain barrier transporters as the CNS supporting and protecting system]Sumio Ohtsuki
Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba ku, Sendai 980 8578, Japan
Yakugaku Zasshi 124:791-802. 2004....
- Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain deliveryM Adenot
Synt em, Nimes, Paris, France
Chemotherapy 53:73-6. 2007..Based on both in vivo and in vitro experimental data, a cell uptake component has been added to our computational model of blood-brain barrier...
- Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugsM Adenot
Synt em, Nimes, Paris, France
Chemotherapy 53:70-2. 2007..High Pe score values are associated with an increase of reported CNS side effects...
- Death-associated protein kinase as a potential therapeutic targetAndrew M Schumacher
Drug Discovery Programme, Department of Molecular Pharmacology and Biological Chemistry, 303 East Chicago Avenue, Ward 8 196, Chicago, IL 60611, USA
Expert Opin Ther Targets 6:497-506. 2002..This article provides a brief summary of relevant research and the rationale that is at the foundation of this opinion...
- Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and developmentSumio Ohtsuki
Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba, Aramaki, Aoba ku, Sendai, 980 8578, Japan
Pharm Res 24:1745-58. 2007..Proteomic studies may also provide important insights into human BBB function. Construction of a human BBB transporter atlas would be a most important advance from the viewpoint of CNS drug discovery and drug delivery to the brain...
- Progress in brain penetration evaluation in drug discovery and developmentXingrong Liu
Roche Palo Alto, 3431 Hillview Avenue S3 2, Palo Alto, CA 94304, USA
J Pharmacol Exp Ther 325:349-56. 2008..2) Selection of P-gp substrates as drug candidates for non-CNS targets can reduce their CNS-mediated side effects...
- 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attentionMarlon Cowart
Department of Neuroscience Research, Abbott Laboratories, Abbott Park, Illinois 60064 6123, USA
J Med Chem 48:38-55. 2005..The potency and selectivity of this compound and of analogues from this class support the potential of H(3) receptor antagonists for the treatment of cognitive dysfunction...
- Donepezil, tacrine and alpha-phenyl-n-tert-butyl nitrone (PBN) inhibit choline transport by conditionally immortalized rat brain capillary endothelial cell lines (TR-BBB)Young Sook Kang
College of Pharmacy, Sookmyung Women s University, Seoul, Korea
Arch Pharm Res 28:443-50. 2005..Accordingly, these results suggest that OCT2 is a candidate for choline transport at the BBB and may influence the BBB permeability of amine drugs...
- Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fractionScott G Summerfield
Department of Drug Metabolism and Pharmacokinetics, Neurology and Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline R and D, New Frontiers Science Park, Third Ave, Harlow, Essex CM19 5AW, UK
J Pharmacol Exp Ther 322:205-13. 2007..These findings corroborate recent reports in the literature that brain penetration is a function of both rate and extent of drug uptake into the CNS...
- New aspects of the blood-brain barrier transporters; its physiological roles in the central nervous systemSumio Ohtsuki
Department of Molecular Biopharmacy and Genetics, Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba ku, Sendai, Japan
Biol Pharm Bull 27:1489-96. 2004..Clarifying the physiological roles of BBB transport systems should give us important information allowing the development of better CNS drugs and improving our understanding of the relationship between CNS disorders and BBB function...
- Expression and function of cytochrome p450 in brain drug metabolismR P Meyer
Pathologisches Institut, Abt Neuropathologie, Neurozentrum, Universitatsklinik Freiburg, Breisacher Strasse 64, D 79106 Freiburg, Germany
Curr Drug Metab 8:297-306. 2007..The understanding of brain P450 function appears to be of major interest in long-term drug mediated therapy of neurological diseases...
- Neuropharmacological evaluation of Ginkgo biloba phytosomes in rodentsSuresh R Naik
Department of Pharmacology and Toxicology, Principal K M Kundnani College of Pharmacy, Jote Joy Building, Rambhau Salgaonkar Marg, Cuffe Parade, Colaba, Mumbai 400 005, India
Phytother Res 20:901-5. 2006..However, the phytosomes failed to show anticonvulsant activity. The observations suggest that the G. biloba phytosomes possess moderate antiamnestic/nootropic activity...
- The influence of some aminoalkanolic xanthone derivatives on central nervous and cardiovascular systems in rodentsTadeusz Librowski
Department of Pharmacodynamics, Faculty of Pharmacy, Medical College, Jagiellonian University, Krakow, Poland
Boll Chim Farm 143:267-74. 2004....
- Correlation of blood-brain penetration using structural descriptorsAlan R Katritzky
Center for Heterocyclic Compounds, Department of Chemistry, University of Florida, Gainesville, FL 32611, USA
Bioorg Med Chem 14:4888-917. 2006..781 and standard deviation s2=0.123. The 'consensus model' of ISIDA gave R2=0.872 and s2=0.047. The developed models were successfully validated using the central nervous system activity data of an external test set of 40 drug molecules...
- The blood-brain barrier: bottleneck in brain drug developmentWilliam M Pardridge
Department of Medicine, UCLA, Los Angeles, California 90024, USA
NeuroRx 2:3-14. 2005..This provides the platform for CNS drug delivery programs, which should be developed in parallel with traditional CNS drug discovery efforts in the molecular neurosciences...
- Design and synthesis of a maximally diverse and druglike screening library using REM resin methodologyD Barn
Lead Discovery Chemistry, Organon Laboratories Ltd, Newhouse, ML1 5SH, Scotland
J Comb Chem 3:534-41. 2001..Encouragingly, hits have been identified from high-throughput screening of this library, such as compound 6, which has an affinity of 1.02 microM for the GlyT(2) transporter...
- Membrane transporter proteins: a challenge for CNS drug developmentFrançois Girardin
Unit of Clinical Psychopharmacology, Geneva University Hospitals, Chênes Bourg, Geneva, Switzerland
Dialogues Clin Neurosci 8:311-21. 2006..They are ATP-independent polypeptides principally expressed at the basolateral membrane of brain capillary and choroid plexus endothelial cells that also mediate drug transport through central nervous system barriers...
- Prediction of CNS activity of compound libraries using substructure analysisOla Engkvist
CallistoGen AG, Neuendorfstrasse 24b, D 16761 Hennigsdorf, Germany
J Chem Inf Comput Sci 43:155-60. 2003..SUBSTRUCT separates the data sets with approximately 80% accuracy. Substructural analysis also shows surprisingly large differences in substructure profiles between CNS active and nonactive drugs...
- Nanobiotechnology-based drug delivery to the central nervous systemK K Jain
Jain PharmaBiotech, Basel, Switzerland
Neurodegener Dis 4:287-91. 2007..Drug delivery across the blood-brain barrier (BBB) is a major limitation in the treatment of central nervous system (CNS) disorders. Several approaches are being investigated to improve drug delivery across the BBB...
- Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substratesMarc Adenot
Synt em, Parc Scientifique G Besse, 30000 Nimes, France
J Chem Inf Comput Sci 44:239-48. 2004..Moreover, a "CNS drugs" map, including P-gp substrates and accurately reflecting the in vivo behavior of drugs, is proposed as a tool for CNS drug virtual screening...
- A role for fMRI in optimizing CNS drug developmentDavid Borsook
Imaging Center for Drug Development ICD, McLean Hospital, Department of Psychiatry, USA
Nat Rev Drug Discov 5:411-24. 2006..fMRI can help optimize CNS drug discovery by providing a key metric that can increase confidence in early decision-making, thereby improving success rates and reducing risk, development times and costs of drug development...
- Novel G-protein-coupled receptor genes expressed in the brain: continued discovery of important therapeutic targetsDennis K Lee
Department of Pharmacology, University of Toronto, Medical Science Building, 8 Taddle Creek Rd Rm 4352, Toronto, Ontario M5S 1A8, Canada
Expert Opin Ther Targets 6:185-202. 2002..Equipped with proven ligand identification strategies, the characterisation of all orphan GPCRs and the exploitation of their exciting potential as targets for the discovery of novel drugs is anticipated...
- Pharmacokinetics of Gastrodin in rat plasma and CSF after i.n. and i.vQiao Wang
Department of Pharmaceutical Analysis and Drug Metabolism, College of Pharmaceutical Sciences, Zi Jin Gang Campus, Zhejiang University, Hangzhou, Zhejiang 310058, PR China
Int J Pharm 341:20-5. 2007..The drug targeting index (DTI) was 12.34. In conclusion, intranasal administration of Gastrodin is a promising alternative to traditional administration. Olfactory mucosa did present another pathway for transport Gastrodin to the brain...
- Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategiesMathew W Smith
Pharmaceutical Cell Biology, Welsh School of Pharmacy, Cardiff University, Redwood Building, Cardiff CF10 3XF, UK
J Drug Target 14:191-214. 2006....
- Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapyDavid S Miller
Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA
Pharmacol Rev 60:196-209. 2008..Finally, several steps in signaling are potential therapeutic targets that could be used to modulate P-glycoprotein activity in the clinic...
- Drug delivery to brain by microparticulate systemsH Suheyla Kas
Department of Pharmaceutical Technology, University of Hacettepe, Sihhiye, Ankara, Turkey
Adv Exp Med Biol 553:221-30. 2004..1). The purpose of this paper is to summarise the methods for BBB permeability modifications and to focus on various examples in delivering drugs, especially neuroncology and neuroactive drugs, to brain by microparticulate systems...
- Cerebral uptake of drugs in humansRichard N Upton
Department of Anaesthesia and Intensive Care, Royal Adelaide Hospital, Adelaide, South Australia, Australia
Clin Exp Pharmacol Physiol 34:695-701. 2007..6. Continuing to exploit and develop these methods may provide new avenues to enhance the safety and efficacy of cerebro-active drugs in clinical practice...
- The blood-brain barrier choline transporter as a brain drug delivery vectorD D Allen
Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, 79106 1712, USA
Life Sci 73:1609-15. 2003..Future work is being completed to determine if other cationic or positively charged therapeutics can be effectively delivered to brain via this carrier...
- [Breaking down barriers--about the art of escorting drugs into the brain]Ulrika Kahl
Lakartidningen 100:136-7. 2003
- Structure-activity relationships and effects on neuroactive steroid synthesis in a series of 2-phenylimidazo[1,2-a]pyridineacetamide peripheral benzodiazepine receptors ligandsGiuseppe Trapani
Dipartimento Farmaco Chimico, Facolta di Farmacia, Universita degli Studi di Bari, Via Orabona 4, 70125 Bari, Italy
J Med Chem 48:292-305. 2005..Compound 3 exhibited very marked effects on the peripheral and central synthesis of neuroactive steroids, while 36 (potent at subnanomolar level) showed a slight ability to affect neuroactive steroid content in the cerebral cortex...
- The role of molecular imaging in drug discovery and developmentR J Hargreaves
Imaging and Proteomics, Merck Research Laboratories, Merck and Co Inc, West Point, Pennsylvania, USA
Clin Pharmacol Ther 83:349-53. 2008..Molecular imaging can be used to improve the cost-effectiveness of studying unprecedented mechanisms, decrease cycle time, and improve drug pipeline quality...
- Validation of a motor activity system by a robotically controlled vehicle and using standard reference compoundsJohn P Patterson
Investigational and Regulatory Safety Pharmacology, Schering Plough Research Institute, Lafayette, NJ 07848, USA
J Pharmacol Toxicol Methods 52:159-67. 2005..4.01, Hamilton-Kinder, LLC, for use in a good laboratory practices (GLP) Safety Pharmacology laboratory...
- Spectrum of effects detected in the rat functional observational battery following oral administration of non-CNS targeted compoundsWilliam S Redfern
Safety Assessment UK, AstraZeneca R and D Alderley Park, Cheshire SK10 4TG, UK
J Pharmacol Toxicol Methods 52:77-82. 2005....
- Region-specific effects of brain corticotropin-releasing factor receptor type 1 blockade on footshock-stress- or drug-priming-induced reinstatement of morphine conditioned place preference in ratsJishi Wang
Department of Pharmacology, The Affiliated Hospital of Guiyang Medical College, Guiyang 550004, China
Psychopharmacology (Berl) 185:19-28. 2006..However, the brain sites involved in the effect of CP-154,526 on footshock-induced reinstatement of opiate seeking are unknown...
- Sensorimotor deficits and increased brain nicotinic acetylcholine receptors following exposure to chlorpyrifos and/or nicotine in ratsMohamed B Abou-Donia
Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
Arch Toxicol 77:452-8. 2003..These data suggest that exposure to either nicotine or chlorpyrifos or a combination of the two may impair neurobehavioral performance and affect the central nervous system cholinergic pathways...
- Changes of [3H]MK-801, [3H]muscimol and [3H]flunitrazepam binding in rat brain by the prolonged ventricular infusion of transformed ginsenosidesSoyong Jang
Department of Neuroscience, College of Medicine, Ewha University, Seoul, Korea
Neurochem Res 29:2257-66. 2004..These results suggest that biotransformed ginsenoside Rh2 and compound K could play an important role in the biological activities in the central nervous systems and neurodegenerative disease...
- A systematic review of currently available pharmacological neuroprotective agents as a sole intervention before anticipated or induced cardiac arrestManuela Weigl
Department of Anaesthesiology and General Intensive Care, Division of Cardiothoracic and Vascular Anaesthesia and Intensive Care, University Hospital Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
Resuscitation 65:21-39. 2005....
- A pyridinium-substituted analog of the TRH-like tripeptide pGlu-Glu-Pro-NH2 and its prodrugs as central nervous system agentsK Prokai-Tatrai
Department of Medicinal Chemistry, College of Pharmacy, University of Florida, 1600 Archer Road, Gainesville, FL 32610 0485, USA
Med Chem 1:141-52. 2005..The novel analog maintained its antidepressant potency but showed reduced analeptic action compared to [Glu2]TRH; thus, an increase in the selectivity of CNS-action was obtained by the incorporation of the pyridinium moiety...
- Positron emission tomography in central nervous system drug discovery and developmentMalcolm Cooper
Department of Radiology, University of Chicago, 2843 West Rascher, Chicago, IL 60625, USA
Neuroimaging Clin N Am 13:851-6, xi. 2003..One particular approach, built around [18F]fluordeoxyglucose positron emission tomography, is described...
- Central nervous system drug development: an integrative biomarker approach toward individualized medicineB Gomez-Mancilla
Neuroscience Biomarker Development, Novartis Pharma, CH 4002 Basel, Switzerland
NeuroRx 2:683-95. 2005..The present review represent an effort to illustrate the integration of such technologies in drug development supporting the path of individualized medicine...
- Antibody-based validation of CNS ion channel drug targetsKenneth J Rhodes
Discovery Neurobiology, Biogen Idec, Cambridge, MA 02142, USA
J Gen Physiol 131:407-13. 2008
- [Pharmacological effects of volatile oil of Valeriana amurensis on CNS]Jun kai Wu
Pharmaceutical College, Heilongjiang University of Chinese Medicine, Harbin 150040, China
Zhong Yao Cai 30:977-80. 2007..To study the pharmacological effects of volatile oil of Valeriana amurensis on central nervous system...
- [Development of new drugs targeting glial cells]Yoshihisa Kudo
Nihon Yakurigaku Zasshi 130:185-92. 2007
- Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine: central nervous system effectsKevin A O'Connor
Department of Psychology and Center for Neuroscience, University of Colorado, Boulder, CO 80309, USA
Cytokine 24:254-65. 2003..Nonetheless, these data suggest that HMGB1 may play a role as an endogenous pyrogen and support the concept that HMGB1 has proinflammatory characteristics within the central nervous system...
- [Central nervous system diseases induced by drug therapies]Masahiro Nomoto
Nihon Naika Gakkai Zasshi 96:1580-4. 2007
- Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depressionPaul R Gard
University of Brighton, School of Pharmacy and Biomolecular Sciences, UK
Expert Opin Ther Targets 8:7-14. 2004..Such effects, if proven, could promote the use of such agents in the treatment of hypertension coexisting with depression or anxiety...
- Polymeric nanoparticles for the drug delivery to the central nervous systemGiovanni Tosi
University of Modena and Reggio Emilia, Department of Pharmaceutical Sciences, Italy
Expert Opin Drug Deliv 5:155-74. 2008..This approach has been recently considered for the therapy of brain diseases. The major problem in accessing the CNS is linked to the presence of the blood-brain barrier...
- Reading and writing the blood-brain barrier: relevance to therapeuticsBarry M Czeisler
Case Western Reserve University School of Medicine, Cleveland, OH, USA
Recent Pat CNS Drug Discov 1:157-73. 2006..These techniques for both "reading" and "writing" the BBB will help new and old medications to reach their pharmacological targets in the CNS...
- Types of medication errors in North Carolina nursing homes: a target for quality improvementRichard A Hansen
Division of Pharmaceutical Outcomes and Policy, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
Am J Geriatr Pharmacother 4:52-61. 2006..Gaining a better understanding of the types of medications commonly involved in medication errors in nursing homes would be an important step toward quality improvement...
- Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brainPhilip H Elsinga
PET Center, Groningen University Hospital, Groningen, The Netherlands
Mol Imaging Biol 7:37-44. 2005..0 after full modulation with CsA. By quantitative PET measurement of P-gp function, the dose of modulators required to increase the concentration of CNS drugs may be determined, which may result in improved drug therapy...
- Clinical drugs that interact with St. John's wort and implication in drug developmentYuan Ming Di
Divison of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, Victoria 3083, Australia
Curr Pharm Des 14:1723-42. 2008..g. digoxin, ivabradine, warfarin, verapamil, nifedipine and talinolol), central nervous system agents (e.g...
- Unfilled prescriptions of medicare beneficiaries: prevalence, reasons, and types of medicines prescribedJae Kennedy
Department of Health Policy and Administration, College of Pharmacy, Washington State University, PO Box 1495, Spokane, WA, 99210 1495, USA
J Manag Care Pharm 14:553-60. 2008..Medicare beneficiaries have high rates of chronic illness and prescription medication use, making this population particularly vulnerable to nonadherence. Failure to fill prescribed medication is a key component of nonadherence...
- Current and investigational antiobesity agents and obesity therapeutic treatment targetsHarold E Bays
FACP Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Ave, Louisville, KY 40213, USA
Obes Res 12:1197-211. 2004..Investigational antiobesity agents consist of 1) central nervous system agents that affect neurotransmitters or neural ion channels, including antidepressants (bupropion), selective ..
- Transcranial magnetic stimulation: applications for neuropsychopharmacologySeppo Kahkonen
BioMag Laboratory, Engineering Centre, Helsinki University Central Hospital and Cognitive Brain Research Unit, Department of Psychology, University of Helsinki, Helsinki, Finland
J Psychopharmacol 18:257-61. 2004..Taken together, TMS provides a new insight to the actions of central nervous system drugs at the cortical level...
- Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical dataJ Cory Kalvass
School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
J Pharmacol Exp Ther 323:346-55. 2007....
- Transcranial route of brain targeted delivery of methadone in oilW Pathirana
Department of Pharmacology and Pharmacy, Faculty of Medicine, University of Colombo, Kynsey Road, Colombo 8, Sri Lanka
Indian J Pharm Sci 71:264-9. 2009..Therefore, it is possible to deliver central nervous system drugs through the proposed transcranial route when suitably formulated...
- An economic assessment of the extent of medication use and wastage among families in Saudi Arabia and Arabian Gulf countriesHisham S Abou-Auda
College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
Clin Ther 25:1276-92. 2003..To this end, medication wastage is an unnecessary burden on an already fiscally restrained health care system...
- Functional expression of taurine transporter and its up-regulation in developing neurons from mouse cerebral cortexTakuya Fujita
Department of Biochemical Pharmacology, Kyoto Pharmaceutical University, Misasagi, Yamashina ku, Kyoto, 607 8414, Japan
Pharm Res 23:689-96. 2006..In the present study, we investigate the characteristics of taurine transport in primary cultures of neurons from mouse cerebral cortex to understand the possibility that taurine might attenuate the effects of central nervous system drugs...
- Pattern of acute food, drug, and chemical poisoning in Sari City, Northern IranAmirhossein Ahmadi
Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
Hum Exp Toxicol 29:731-8. 2010..Establishing poison information centers in different parts of the country, preparing national treatment guidelines, training healthcare providers, and ensuring easy availability of the antidotes are also recommended...
- Medication errors recovered by emergency department pharmacistsJeffrey M Rothschild
Division of General Medicine, Brigham and Women s Hospital, Boston, MA, USA
Ann Emerg Med 55:513-21. 2010..We assess the impact of emergency department (ED) pharmacists on reducing potentially harmful medication errors...
- Brain uptake of ketoprofen-lysine prodrug in ratsMikko Gynther
School of Pharmacy, University of Eastern Finland, Kuopio, Finland
Int J Pharm 399:121-8. 2010..In addition, our results show that although lysine or ketoprofen are not LAT1-substrates themselves, by combining these molecules, the formed prodrug has affinity for LAT1...
- A survey on the extent of medication storage and wastage in urban Iranian householdsA H Zargarzadeh
Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Iran
Clin Ther 27:970-8. 2005..The limited resources of developing countries warrant more careful assessments of current national drug policies...
- Potential risks and prevention, Part 1: Fatal adverse drug eventsW N Kelly
Department of Pharmacy Administration, Southern School of Pharmacy, Mercer University, 3001 Mercer University Drive, Atlanta, GA 30341 4155, USA
Am J Health Syst Pharm 58:1317-24. 2001..1 million. A review of published case reports of ADEs for 1976-95 yielded information on possible risk factors for fatal ADEs and on which events may have been preventable...
- Pattern of drug prescription and utilization among Bam residents during the first six months after the 2003 Bam earthquakeGholamreza Sepehri
Physiology and Pharmacology Department, Neuroscience Research Center, Kerman University of Medical Sciences, Kerman, Iran
Prehosp Disaster Med 21:396-402. 2006..3 on the Richter scale struck southeastern Iran, decimating the city of Bam. In this study, the most frequently utilized and prescribed drugs for Bam outpatients during the first six months after the Bam Earthquake were investigated...
- Drug utilization and potentially inappropriate drug use in elderly residents of a community in Istanbul, TurkeyP Ay
Department of Public Health, School of Medicine, Marmara University, Istanbul, Turkey
Int J Clin Pharmacol Ther 43:195-202. 2005..This study investigates drug utilization and estimates the prevalence of potentially inappropriate drug use in a Turkish population aged 70 years or older...
- Drug consumption among Polish centenariansA Rajska-Neumann
Department of Geriatrics and Gerontology, University of Medical Science, 6 Swiecickiego Street, 60 681 Poznan, Poland
Arch Gerontol Geriatr 53:e29-32. 2011..To conclude, the mean number of drugs, the prevalence of polypharmacy, and the tendency for potential inappropriateness of treatment are lower among Polish centenarians comparing to the common elderly...
- Influence of lipophilicity on the interactions of N-alkyl-4-phenyl-1,2,3,6-tetrahydropyridines and their positively charged N-alkyl-4-phenylpyridinium metabolites with cytochrome P450 2D6Amit S Kalgutkar
Pharmacokinetics, Dynamics, and Metabolism Department, Pfizer Global Research and Development, Groton, Connecticut 06340, USA
Drug Metab Dispos 31:596-605. 2003..This phenomenon appears to be a common theme among several cyclic tertiary amine-containing anti-depressants and should be taken into consideration when designing central nervous system agents devoid of CYP2D6 substrate properties.
- Inappropriate medication prescribing for elderly ambulatory care patientsMargie Rauch Goulding
Office of Analysis, Epidemiology, and Health Promotion at the National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD 20782, USA
Arch Intern Med 164:305-12. 2004..Inappropriate medication use in elderly patients has been linked to a large share of adverse drug reactions and to excess health care utilization...
- Tenfold medication dose prescribing errorsTimothy S Lesar
Albany Medical Center, Mail code 85, 43 New Scotland Ave, Albany, New York 12208 3412, USA
Ann Pharmacother 36:1833-9. 2002..Few systematic evaluations of the characteristics and causes of tenfold medication dosage prescribing errors have been performed...
- Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug developmentB Andree
Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Stockholm, Sweden
Nucl Med Biol 27:515-21. 2000..These studies reviewed here illustrate and corroborate that quantitative neuroimaging of receptor binding has potential for the evaluation and dose finding of new central nervous system drugs...
- Discontinuation and reinstitution of medications during the perioperative periodSteven E Pass
Department of Pharmacy Services, University Hospital, Cincinnati, OH 45219 2316, USA
Am J Health Syst Pharm 61:899-912; quiz 913-4. 2004..the discontinuation and reinstitution of long-term therapies, including cardiovascular agents, anticoagulants and antiplatelet agents, central nervous system agents, and herbal medicines, in the perioperative period are discussed.
- Potential risks and prevention, Part 4: Reports of significant adverse drug eventsW N Kelly
Department of Pharmacy Administration, Southern School of Pharmacy, Mercer University, 3001 Mercer University Drive, Atlanta, GA, USA
Am J Health Syst Pharm 58:1406-12. 2001..1 million. A summary analysis of more than 1500 published case reports of ADEs for 1976-97 yielded information on possible risk factors for drug-related deaths, disabilities, and life threats and on which events may have been preventable...
- Pharmacogenomics of antipsychotics efficacy for schizophreniaRamon Cacabelos
EuroEspes Biomedical Research Center, Institute for CNS Disorders and Genomic Medicine, Bergondo, Coruna, Spain
Psychiatry Clin Neurosci 65:3-19. 2011....
- Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studiesLuca Cucullo
Division of Cerebrovascular Research, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio 44195, USA
J Cereb Blood Flow Metab 28:312-28. 2008..Pretreatment with ibuprofen (0.125 mmol/L) prevented BBB failure by decreasing the inflammatory response after flow cessation/reperfusion...
- Examination of multiple medication use among TRICARE beneficiaries aged 65 years and olderAndrea Linton
OASD HA, 5111 Leesburg Pike, Suite 810, Falls Church, VA 22041 3206, USA
J Manag Care Pharm 13:155-62. 2007..The simultaneous use of multiple prescription medications has been associated with an increased risk of adverse drug events and other drug-related complications, especially in the elderly...
- Neurotrophin Blood/Brain Barrier Delivery in IschemiaWilliam Pardridge; Fiscal Year: 2006..unreadable] [unreadable]..
- PTS1 Regulation of Brain Met Enk Levels in AlcoholismWilliam Banks; Fiscal Year: 2004..abstract_text> ..
- BLOOD BRAIN BARRIER LARGE NEUTRAL AMINO ACID TRANSPORTERWilliam Pardridge; Fiscal Year: 2003..These studies will provide new molecular biological information on a crucial transporter at the blood-brain barrier that regulates the supply in the brain of essential amino acids. ..
- Multiplexed flow cytometry screens for RGS inhibitorsRichard Neubig; Fiscal Year: 2007..The ultimate aim of this project is the identification of selective small molecule inhibitors of RGS action. This will provide important chemical tools and accelerate the development of novel therapeutics. ..
- AMPHETAMINE ENHANCED STROKE RECOVERY--BURKE SRCI GROUPLarry Goldstein; Fiscal Year: 2002..However the treatment duration will be increased to a total of 10 sessions. ..
- STRUCTURAL BASIS OF RECEPTOR/G PROTEIN FUNCTIONRichard Neubig; Fiscal Year: 2004..This work should greatly improve our understanding of the structural and mechanistic basis of RG coupling and should facilitate the design of drugs that target particular G protein subunit combinations. ..
- Prion Transport Across the Blood-Brain BarrierWilliam Banks; Fiscal Year: 2009..To cause disease, prions must cross the blood-brain barrier to enter the brain. We will determine how prions cross the BBB. Knowing how prions enter the brain should lead to strategies on how to prevent prion diseases. ..
- Mechanisms of HIV Transport Across the BBBWilliam Banks; Fiscal Year: 2004....
- AIDS Neurotherapeutics and BBB Drug EffluxWilliam Pardridge; Fiscal Year: 2007..This work provides the basis for future drug discovery of AET blockers, which can be used as co-drugs to increase CNS penetration of HAART drugs. ..
- REGULATION OF BBB GLUT1 GLUCOSE TRANSPORTERWilliam Pardridge; Fiscal Year: 2002..These studies will provide insight into molecular mechanisms of regulation of a step crucial to the maintenance of cerebral intermediary metabolism, i.e., the continuous transport of glucose across the blood-brain barrier in vivo. ..
- MIDCAREER INVESTIGATOR AWARD IN CEREBROVASCULAR RESEARCHLarry Goldstein; Fiscal Year: 2004....
- Antisense imaging of brain gene expression in vivoWilliam Pardridge; Fiscal Year: 2005..This technology could be extended to humans and to other organs. At present, there is no parallel technology that enables the non-invasive in vivo imaging of "any gene in any person," which is the goal of this work. ..
- Non-Viral Gene Targeting to the BrainWilliam Pardridge; Fiscal Year: 2008..abstract_text> ..
- Opiate Addiction and HIV-1 Induced Release of CytokinesWilliam Banks; Fiscal Year: 2006....
- Angiogenic determinants of endogenous adult neurogenesisSteven Goldman; Fiscal Year: 2008....
- mGluR4 Potentiators as a Treatment for Parkinson's DiseaseP Conn; Fiscal Year: 2007..This high throughput screen will provide the basis for future studies aimed at developing allosteric potentiators of mGluR4 that are suitable for clinical testing. [unreadable] [unreadable]..
- DELIRIUM IN PERSONS WITH DEMENTIADonna Fick; Fiscal Year: 2007..Ultimately, the results from this and subsequent studies should improve the lives of persons with dementia and their caregivers by decreasing delirium-related complications and hospitalizations. [unreadable] [unreadable] [unreadable]..
- High End Computing for PET/SPECTDEAN WONG; Fiscal Year: 2007..unreadable] [unreadable] [unreadable]..
- Functional effects of mGluR potentiators in the CNSP Jeffrey Conn; Fiscal Year: 2010....
- Protective Influence of Residential Learning CommunitiesSEAN MCCABE; Fiscal Year: 2006..At each measurement point, participants will complete a set of measures that assess substance use behaviors and constructs addressed by RLCs. ..
- Nursing Home IT: Optimal Medication and Care DeliverySusan Horn; Fiscal Year: 2006..Distill and summarize lessons learned about what is critical for successful implementation of HIT in nursing homes, including facilitators, barriers, and strategies to address them. ..
- Novel Glutamatergic Detoxification StrategiesJohn Krystal; Fiscal Year: 2006..abstract_text> ..
- Induction of Striatal Regeneration in Huntington's DiseaseSteven Goldman; Fiscal Year: 2009....
- Sites and Mechanisms of Ethanol Action in P2X receptorsDARYL DAVIES; Fiscal Year: 2009....
- Blood Brain Barrier Physiology and HIV DementiaHOWARD GENDELMAN; Fiscal Year: 2007..The data acquired could provide new insights and therapeutic intervention strategies for monocyte BBB trafficking during progressive HIV-1 infection in brain tissue. ..
- DIETARY OBESITYGeorge Bray; Fiscal Year: 2007..We now propose these well founded, important and exciting studies which will provide critical new insights into anatomical, physiological and molecular mechanisms by which high levels of dietary fat induce obesity. ..
- AMINO ACID NEUROTRANSMITTER DYSREGULATION IN ALCOHOLISMJohn Krystal; Fiscal Year: 2008..abstract_text> ..
- Regulation of Hypothalamic Sleep-wake Neuronal SystemNOOR ALAM; Fiscal Year: 2008..This will contribute to the search for more targeted and specific therapeutic strategies for sleep disorders. ..
- Estrogens for Alcoholism & Its Neurological ConsequencesJames Simpkins; Fiscal Year: 2008..the proposed studies will provide new knowledge on the mechanism of estrogen protection from the consequences of EW and determine if estrogens are potential pharmacotherapies for alcoholism and its consequences [unreadable] [unreadable]..
- Topiramate for alcohol and cocaine dependenceKyle Kampman; Fiscal Year: 2008..abstract_text> ..
- Sexual Orientation, Substance Use and Mental HealthSEAN MCCABE; Fiscal Year: 2008..unreadable] [unreadable] [unreadable] [unreadable]..
- A High Throughput Screen for Inhibitors of a Novel Necrotic Cell Death PathwayJunying Yuan; Fiscal Year: 2007..Necroptosis has been shown to be a promising target for the treatment of stroke as it represents a type of delayed cell death in stroke and offers an extended time window for therapy. [unreadable] [unreadable] [unreadable]..
- The Amygdala, Individual Differences, and Conditioned HyperactivityMary Cain; Fiscal Year: 2007..The findings of these experiments are intended to advance the understanding of vulnerability for stimulant abuse, and will potentially lead to better prevention and treatment interventions. [unreadable] [unreadable] [unreadable]..
- 2008 AUA/SBUR Summer Research ConferenceArthur Burnett; Fiscal Year: 2008..unreadable] [unreadable] [unreadable]..
- Validation of the NINDS VCI Neuropsychology ProtocolsDavid Nyenhuis; Fiscal Year: 2009..Reliable and valid VCI neuropsychology test protocols are a necessary first step to improved diagnostic criteria and a better understanding of both the mechanisms of VCI and the development of new treatment options. ..
- Life Cycle Effects of Health Insurance on Elderly HealthJalpa Doshi; Fiscal Year: 2006..We will use these estimates to simulate the effect of changes in the age of Medicare eligibility on health, medical service use and Medicare expenditure. ..
- Genetics of Attention Deficit-Hyperactivity DisorderJames Swanson; Fiscal Year: 2006..Genomic haplotypes", meaning haplo-specific genotypes at more than one locus, will be defined and tested for possible interactive roles among the genes. ..
- CONTROL OF SLEEP AND AROUSALNOOR ALAM; Fiscal Year: 2003..These pharmacological manipulations and analytical procedures will help understanding of the adenosinergic and GABAergic mechanisms that shape the discharge patterns of the MBF neurons across the sleep-waking cycle. ..
- AMINO ACID NEUROTRANSMITTER DYSREGULATION IN ALCOHOLISMJohn Krystal; Fiscal Year: 2003..In summary, this K02 award would foster my academic development and enable me to better contribute to the building of pathophysiologic models of alcoholism that can guide medications development for this disorder. ..
- Symposium on Neuroimaging in AlcoholismJohn Krystal; Fiscal Year: 2003..A call for abstracts also will bring forward names and ideas from other groups that might be added to the main program. Young Investigator travel scholarships will be considered. ..
- UCI-CFC Projects on School ReadinessJames Swanson; Fiscal Year: 2002....
- BEHAVIORAL EFFECTS OF NIGRAL D1 ANTAGONISMJohn Salamone; Fiscal Year: 2001....
- BASAL GANGLIA FMRI IN NORMAL AND PARKINSONIAN PATIENTSAlice Flaherty; Fiscal Year: 2002..abstract_text> ..
- TREATMENT FOR ALCHOLISM: A PRIMATE MODELKELLY COSGROVE; Fiscal Year: 2002..Thus, the effects of bremazocine and naltrexone on ethanol self-administration as a function of sex will be investigated. ..
- CHOLINERGIC AND OPIATE MECHANISMS IN DRUG REINFORCEMENTShafiqur Rahman; Fiscal Year: 2002....
- NEURONAL ELECTROPHYSIOLOGY IN HIV DEMENTIAHOWARD GENDELMAN; Fiscal Year: 2001....
- IMAGING DOPAMINE/SEROTONIN MECHANISMS IN COCAINE CRAVINGDEAN WONG; Fiscal Year: 2003..Testing of these hypotheses will provide novel and fundamental answers to craving mechanisms. ..
- MECHANISM & FUNCTIONS OF ICH-3 IN APOPTOSIS/INFLAMMATIONJunying Yuan; Fiscal Year: 2001..These works will have direct implication in control of apoptosis in normal and inflammatory conditions. ..
- The Amygdala and Amphetamine Self-AdministrationMary Cain; Fiscal Year: 2003..The findings from these experiments are intended to advance the understanding of vulnerability for stimulant abuse, and will potentially lead to better prevention and treatment interventions. ..
- Dedicated High Performance Human Brain/Preclinical PETDEAN WONG; Fiscal Year: 2004..abstract_text> ..
- RISK MARKERS FOR DEMENTIA AFTER STROKEDavid Nyenhuis; Fiscal Year: 2004..They state that refinement in our knowledge of mechanisms and causes for dementia in stroke patients may lead to an improvement in prevention and treatment strategies. ..
- GREAT LAKES REGIONAL NODECHARLES SCHUSTER; Fiscal Year: 2004..In summary we believe that the GLRN has a very strong research team, the administrative infrastructure to manage the program, and enthusiastic CTPs anxious to participate in the NIDA CTN. ..
- THE ROLE OF PEUTZ JEGHER GENE IN APOPTOSISJunying Yuan; Fiscal Year: 2005..We will also search for evidence of apoptosis inhibition in the polyps regions of the intestinal samples from Peutz-Jegher patients. ..
- Epidemiology of Prescription Drug Abuse in the United StatesSEAN MCCABE; Fiscal Year: 2007..It will help identify risk factors for substance abuse. Most importantly, the findings will provide guidance for the prevention, assessment, and treatment of prescription drug abuse. [unreadable] [unreadable]..
- QUANTITATIVE FUNCTION IN MOTOR NEURON DISEASEEric Sorenson; Fiscal Year: 2004..This will become increasingly important as our population ages, increasing demands for medical and social resources. ..
- Nonmedical Prescription Drug Use among College StudentsSEAN MCCABE; Fiscal Year: 2005..Findings from this research will have important implications for the understanding of the epidemiology, prevention and treatment of prescription drug abuse. ..
- 2005 Gordon Conference on CatecholaminesDavid Sulzer; Fiscal Year: 2005..abstract_text> ..
- Neuroadaptations underlying the transition to addiction.Osnat Ben Shahar; Fiscal Year: 2006..Together, these experiments will illuminate some of the changes in dopaminergic function that underlie the transition to compulsive drug-use. ..
- Pressure-Based Pharmacological Alcoholism TreatmentsDARYL DAVIES; Fiscal Year: 2005..These agents can form the bases of novel prevention and treatment strategies for alcoholism and alcohol abuse. ..
- LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGEDNunzio Pomara; Fiscal Year: 2005..index of brain white matter organization) contribute most strongly to the acute effects of lorazepam on cognitive/motor performance or postural sway in elderly individuals receiving long-term lorazepam treatment for GAD? ..
- NALTREXONE BLOCKADE OF NMDAJohn Krystal; Fiscal Year: 2002..Thus, the blockade of the rewarding effects of ketamine by naltrexone may provide insight into an important mechanism underlying the psychopharmacology of ethanol and the treatment of alcoholism. ..
- Regulation of adult human oligodendrocyte progenitorsSteven Goldman; Fiscal Year: 2008..abstract_text> ..
- IMAGING DOPAMINE RELEASE/ENDOCRINE CHANGES IN ALCOHOLISMDEAN WONG; Fiscal Year: 2004..If the initial D2 receptor deficits are exacerbated by alcohol abuse one can envision a positive feedback loop hard to break. ..
- Racial Disparities in Older Adults: Impact of Medicare Part DJoseph T Hanlon; Fiscal Year: 2010....
- P33ING1 IN CELLULAR SENESCENCE AND ORGANISIMAL AGINGJunying Yuan; Fiscal Year: 2003..These works will illustrate the role of p33ING1 in mediating cellular senescence in culture and organismal aging in vivo. ..
- Prescription Drug Abuse Among College StudentsSEAN MCCABE; Fiscal Year: 2005....